دورية أكاديمية
أعرض في EDS

Staphylococcus aureus-induced immunosuppression mediated by IL-10 and IL-27 facilitates nasal colonisation.

التفاصيل البيبلوغرافية
العنوان: Staphylococcus aureus-induced immunosuppression mediated by IL-10 and IL-27 facilitates nasal colonisation.
المؤلفون: Kelly AM; Host-Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland., Leech JM; Host-Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland., Doyle SL; Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.; Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland., McLoughlin RM; Host-Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
المصدر: PLoS pathogens [PLoS Pathog] 2022 Jul 01; Vol. 18 (7), pp. e1010647. Date of Electronic Publication: 2022 Jul 01 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, c2005-
مواضيع طبية MeSH: Interleukin-27* , Staphylococcal Infections*/microbiology, Animals ; Cytokines ; Immunosuppression Therapy ; Interleukin-10 ; Interleukin-17 ; Mice ; Staphylococcus aureus
مستخلص: Staphylococcus aureus persistently colonises the anterior nares of a significant proportion of the healthy population, however the local immune response elicited during S. aureus nasal colonisation remains ill-defined. Local activation of IL-17/IL-22 producing T cells are critical for controlling bacterial clearance from the nasal cavity. However, recurrent and long-term colonisation is commonplace indicating efficient clearance does not invariably occur. Here we identify a central role for the regulatory cytokine IL-10 in facilitating bacterial persistence during S. aureus nasal colonisation in a murine model. IL-10 is produced rapidly within the nasal cavity following S. aureus colonisation, primarily by myeloid cells. Colonised IL-10-/- mice demonstrate enhanced IL-17+ and IL-22+ T cell responses and more rapidly clear bacteria from the nasal tissues as compared with wild-type mice. S. aureus also induces the regulatory cytokine IL-27 within the nasal tissue, which acts upstream of IL-10 promoting its production. IL-27 blockade reduces IL-10 production within the nasal cavity and improves bacterial clearance. TLR2 signalling was confirmed to be central to controlling the IL-10 response. Our findings conclude that during nasal colonisation S. aureus creates an immunosuppressive microenvironment through the local induction of IL-27 and IL-10, to dampen protective T cell responses and facilitate its persistence.
Competing Interests: The authors have declared that no competing interests exist.
References: Immunol Lett. 2009 Jun 30;125(1):7-14. (PMID: 19446579)
J Infect Dis. 2011 Jul 15;204(2):253-62. (PMID: 21673036)
Am J Respir Crit Care Med. 2014 May 15;189(10):1250-9. (PMID: 24749506)
J Immunol. 2017 Mar 15;198(6):2352-2365. (PMID: 28167629)
Clin Infect Dis. 2013 Apr;56(8):1067-74. (PMID: 23325428)
Sci Rep. 2017 Nov 30;7(1):16607. (PMID: 29192280)
Respir Res. 2015 Feb 05;16:10. (PMID: 25651926)
Int Forum Allergy Rhinol. 2019 Nov;9(11):1318-1326. (PMID: 31545872)
J Immunol. 2014 Apr 15;192(8):3697-708. (PMID: 24623128)
Int J Mol Sci. 2018 Nov 06;19(11):. (PMID: 30404183)
Glia. 2012 Jan;60(1):29-42. (PMID: 21901759)
Int J Infect Dis. 2017 Nov;64:9-14. (PMID: 28882667)
Front Microbiol. 2018 Oct 08;9:2419. (PMID: 30349525)
J Infect Dis. 2008 Aug 1;198(3):359-66. (PMID: 18557702)
PLoS Pathog. 2012 Dec;8(12):e1003092. (PMID: 23300445)
Front Immunol. 2018 Nov 27;9:2636. (PMID: 30538697)
Thorax. 2014 Oct;69(10):926-37. (PMID: 25074706)
J Infect Dis. 2016 Dec 1;214(11):1744-1751. (PMID: 27651414)
Infect Immun. 2013 Jun;81(6):2070-5. (PMID: 23529621)
Trends Microbiol. 2016 Nov;24(11):872-886. (PMID: 27474529)
Immunity. 2004 Aug;21(2):215-26. (PMID: 15308102)
J Infect Dis. 2010 Sep 15;202(6):924-34. (PMID: 20677941)
J Clin Microbiol. 2006 Jun;44(6):2233-6. (PMID: 16757626)
J Infect Dis. 2009 Mar 1;199(5):625-32. (PMID: 19199541)
Infect Immun. 2018 Nov 20;86(12):. (PMID: 30249747)
Immunity. 2016 Mar 15;44(3):634-646. (PMID: 26982365)
Front Immunol. 2014 Jan 08;4:507. (PMID: 24409186)
N Engl J Med. 2010 Jan 7;362(1):9-17. (PMID: 20054045)
Mucosal Immunol. 2011 May;4(3):261-70. (PMID: 21451501)
Mucosal Immunol. 2016 Nov;9(6):1429-1441. (PMID: 27007677)
mBio. 2016 Aug 09;7(4):. (PMID: 27507829)
J Immunol. 2015 Feb 1;194(3):1100-11. (PMID: 25548227)
PLoS One. 2019 Sep 20;14(9):e0222943. (PMID: 31539406)
Immunology. 2007 Sep;122(1):80-9. (PMID: 17472720)
Sci Rep. 2012;2:606. (PMID: 22930672)
J Clin Invest. 2018 Mar 1;128(3):1026-1042. (PMID: 29400698)
PLoS One. 2021 May 12;16(5):e0247895. (PMID: 33979348)
Infect Immun. 2016 Nov 18;84(12):3575-3583. (PMID: 27736775)
Front Immunol. 2021 Apr 28;12:638917. (PMID: 33995357)
Pathogens. 2019 Mar 17;8(1):. (PMID: 30884909)
Clin Microbiol Infect. 2018 Nov;24(11):1210.e7-1210.e12. (PMID: 29458158)
Infect Immun. 2012 Jun;80(6):2186-93. (PMID: 22451514)
Infect Immun. 2015 Apr;83(4):1587-97. (PMID: 25644014)
Infect Immun. 2018 Feb 20;86(3):. (PMID: 29311230)
J Hepatol. 2009 Sep;51(3):510-9. (PMID: 19608294)
J Leukoc Biol. 2015 Dec;98(6):1003-13. (PMID: 26232453)
Front Immunol. 2020 Apr 30;11:767. (PMID: 32425944)
Clin Microbiol Infect. 2010 Aug;16(8):1312-7. (PMID: 19832714)
CSH Protoc. 2008 Dec 01;2008:pdb.prot5080. (PMID: 21356739)
J Immunol. 2010 Dec 1;185(11):6599-607. (PMID: 21041726)
STAR Protoc. 2020 Dec 31;2(1):100246. (PMID: 33458708)
Microbes Infect. 2007 Oct;9(12-13):1471-7. (PMID: 17913546)
Nat Commun. 2017 Jun 05;8:15632. (PMID: 28580944)
J Allergy Clin Immunol. 2014 Oct;134(4):944-954.e8. (PMID: 25051954)
Clin Diagn Lab Immunol. 2001 Nov;8(6):1064-9. (PMID: 11687441)
Lancet. 2004 Aug 21-27;364(9435):703-5. (PMID: 15325835)
Front Microbiol. 2021 Sep 17;12:729053. (PMID: 34603258)
PLoS Pathog. 2014 May 01;10(5):e1004089. (PMID: 24788600)
Cell Death Dis. 2018 Dec 5;9(12):1182. (PMID: 30518854)
Mucosal Immunol. 2020 May;13(3):460-470. (PMID: 31896761)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust; 202846/Z/16/Z United Kingdom WT_ Wellcome Trust
المشرفين على المادة: 0 (Cytokines)
0 (Interleukin-17)
0 (Interleukin-27)
130068-27-8 (Interleukin-10)
تواريخ الأحداث: Date Created: 20220701 Date Completed: 20220718 Latest Revision: 20220721
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9282462
DOI: 10.1371/journal.ppat.1010647
PMID: 35776778
قاعدة البيانات: MEDLINE
الوصف
تدمد:1553-7374
DOI:10.1371/journal.ppat.1010647